GILD vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 07, 2026

GILD

56.3
AI Score
VS
GILD Wins

MRNA

51.3
AI Score

Investment Advisor Scores

GILD

56score
Recommendation
HOLD

MRNA

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric GILD MRNA Winner
Revenue 534.00M 14.76B GILD
Net Income -2.13B -8.47B MRNA
Net Margin -397.9% -57.4% GILD
Operating Income -2.20B -7.81B MRNA
ROE -31.4% -71.6% MRNA
ROA -19.4% -17.2% GILD
Total Assets 10.96B 49.36B GILD
Debt/Equity 0.09 2.22 MRNA
Current Ratio 2.29 1.27 MRNA
Free Cash Flow -1.25B 5.86B GILD

Relative Price Performance (Last 90 Days)

GILD 1M: -1.0% · 3M: -0.4% MRNA 1M: -23.7% · 3M: +20.3%

Current Technical Phase

GILD

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 54

RSI (14): 54.1 · Price: $133.54

MRNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 49

RSI (14): 49.0 · Price: $58.39

Fundamentals Snapshot

Metric GILD MRNA
Market Cap
Forward P/E 13.5 -11.0
Trailing P/E
Revenue (TTM)
Revenue Growth 0.1% 0.0%
Gross Margin 0.8% -0.7%
Operating Margin 0.4% -5.6%
EPS -2.63 -7.88
Dividend Yield 0.02%

Frequently Asked Questions

Based on our detailed analysis, GILD is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.